Company Overview

Pliant Therapeutics, Inc. is a U.S.-based clinical-stage biotechnology company focused on discovering and developing therapies for fibrotic diseases. The company operates within the biotechnology and pharmaceutical industries, with a strategic emphasis on integrin biology and precision medicines designed to address fibrosis-driven conditions across pulmonary, hepatic, and oncology-related indications. Pliant’s core business model centers on advancing proprietary small-molecule integrin inhibitors through clinical development, with future revenue generation expected to derive from product commercialization, licensing arrangements, and potential collaboration agreements if regulatory approvals are achieved.

The company’s primary pipeline includes candidates targeting idiopathic pulmonary fibrosis (IPF), primary sclerosing cholangitis (PSC), and other fibrosis-associated diseases. Its lead product candidate, bexotegrast (PLN-74809), is an oral dual-selective integrin inhibitor targeting αvβ6 and αvβ1 integrins. Pliant positions itself through a differentiated platform focused on integrin-mediated fibrosis pathways, an area that remains relatively underpenetrated compared with broader immunology and oncology markets. Founded in 2015, Pliant evolved from scientific research centered on integrin biology and advanced from early discovery into multiple clinical-stage programs following public financing and its Nasdaq listing under the ticker PLRX.

Business Operations

Pliant operates primarily as a single biotechnology business focused on research and development activities. The company generates no recurring commercial product revenue as of publicly available filings and instead funds operations through equity offerings, strategic financing activities, and collaboration-related payments. Its core operational assets include proprietary integrin-focused discovery platforms, internally developed clinical candidates, intellectual property portfolios, and translational medicine capabilities supporting fibrosis drug development. Key programs include bexotegrast, PLN-101095, and preclinical oncology and fibrosis candidates directed at selective integrin targets.

Operations are concentrated in the United States, particularly through research, clinical development, and corporate functions headquartered in South San Francisco, California. Pliant relies on external contract research organizations, clinical trial sites, and manufacturing partners to support development activities. The company has also engaged in strategic collaborations, including research-related partnerships intended to accelerate discovery efforts and broaden translational capabilities. Public filings identify substantial investment in clinical trial infrastructure, regulatory engagement, and intellectual property protection as central operational priorities.

Strategic Position & Investments

Pliant’s strategic direction is centered on developing therapies that target fibrosis at the molecular signaling level through selective integrin inhibition. The company has prioritized advancing bexotegrast through mid- and late-stage clinical evaluation for pulmonary fibrosis indications while also expanding applications across additional fibrotic diseases. Management has emphasized the potential for oral therapies with differentiated safety and efficacy profiles relative to currently available anti-fibrotic treatments. Clinical development remains the company’s principal investment focus, with significant expenditures directed toward trials, biomarker research, and regulatory preparation.

The company has invested in broadening its fibrosis and oncology pipeline through internal discovery programs and platform expansion rather than large-scale acquisitions. Public disclosures reference continued investment in translational science, medicinal chemistry, and integrin-targeted therapeutic approaches. Pliant’s strategy reflects participation in emerging precision medicine approaches within fibrosis, where validated treatment options remain limited. Data regarding significant subsidiary holdings or extensive portfolio-company ownership is inconclusive based on available public sources.

Geographic Footprint

Pliant Therapeutics is headquartered in South San Francisco, California, within the United States, and conducts the majority of its corporate, research, and development operations domestically. Its clinical programs, however, involve broader international engagement through multicenter clinical trials, third-party manufacturing relationships, and collaborations with research institutions and clinical sites across multiple regions.

The company’s operational influence extends primarily into North America and selected international clinical markets in Europe and other regions participating in fibrosis-related clinical research. While Pliant does not currently maintain a broad commercial infrastructure due to its pre-commercial status, its clinical development strategy reflects an intent to support future regulatory and market access opportunities internationally if product candidates receive approval.

Leadership & Governance

Pliant Therapeutics was co-founded by scientists and biotechnology executives with expertise in fibrosis biology, drug discovery, and translational medicine. The company’s leadership has consistently emphasized a science-driven development philosophy focused on selective integrin targeting, disciplined clinical execution, and long-term value creation through differentiated therapies for severe fibrotic diseases. Governance oversight is provided through a board of directors with biotechnology, pharmaceutical development, and financial leadership experience.

Key executives identified in public filings and company disclosures include:

• Bernard Coulie, M.D., Ph.D. – President and Chief Executive Officer
• Keith Cummings – Chief Financial Officer
• Hans Schambye, M.D., Ph.D. – Chairman of the Board
• Jason R. Carmody, Ph.D. – Chief Business Officer
• Richard B. Hargreaves, Ph.D. – Chief Scientific Officer
• Eric Lefebvre, M.D. – Chief Medical Officer

Leadership communications in investor materials and SEC filings indicate a strategic focus on advancing clinical-stage fibrosis programs, maintaining financial discipline, and leveraging integrin biology expertise to build a differentiated therapeutic pipeline.